EUVIMEDObjevte EUVIMED
CrossrefInformační karta

The Role Of Renal Resistive Index (RRI) As Early Non Invasive Predictor Of Renal Dysfunction And Relation To Estimated GFR In NAFLD Patients

Atteyat Aboelmaged Semeya, Hala Abd-Elhameed Tabl, Naglaa F. AL-Mihy

Journal of Medicine in Scientific Research · 2024-01-01 · 7 (3)

DOI: 10.59299/2537-0928.1394 ↗
AbstraktBibliografické údaje

Abstrakt

Background: Non-alcoholic fatty liver (NAFLD) is the diagnosis of fatty infiltration of the liver (steatosis) in the absence of other reasons, done through histology or imaging, with or without fibrosis or inflammation. We sought to ascertain the function of RRI as early non-invasive predictor of renal dysfunction and the relationship between eGFR and RRI in patients with NAFLD. Methods: This cross-sectional research comprised 250 patients and controls gathered from outpatient clinic of the Hepatogasteroenterology Department, Benha teaching Hospitals. They were split into three groups: group 1 consisted of 100 NASH patients, fibrosis-free or with a history of the condition; group 2 comprised 100 patients with simple steatosis; and group 3 consisted of an additional 50 healthy, normal controls. All patients underwent laboratory investigations including tests for the lipid profile, liver function, kidney function, and fasting blood glucose (FBG) and radiological assessment using an abdominal U/S. Results: RRI and NAFLD fibrosis score were significantly greater in group one in contrast to groups two and three (P0.063, with 100% sensitivity, 60.67% specificity, 62.9% PPV and 100% NPV. Conclusions: We concluded that NAFLD are associated with higher RRI, NAFLD fibrosis score, FBG, serum creatinine, hazardous lipid profile and liver enzymes and lower eGFR.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →